Beguelin, Wendy

Publications

Sort by

Co-Author Network

selected publications

Cooperative super-enhancer inactivation caused by heterozygous loss of CREBBP and KMT2D skews B cell fate decisions and yields T cell-depleted lymphomas. bioRxiv : the preprint server for biology. 2023 Article GET IT
An Aged/Autoimmune B-cell Program Defines the Early Transformation of Extranodal Lymphomas. Cancer discovery. 2023 Editorial Article GET IT
Times cited: 3
Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma. The Journal of clinical investigation. 2022 Academic Article GET IT
Times cited: 10
Histone 3 Methyltransferases Alter Melanoma Initiation and Progression Through Discrete Mechanisms. Frontiers in cell and developmental biology. 2022 Academic Article GET IT
Times cited: 62
Intravital three-photon microscopy allows visualization over the entire depth of mouse lymph nodes. Nature immunology. 2022 Academic Article GET IT
Times cited: 14
Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies. Frontiers in cell and developmental biology. 2022 Review GET IT
Times cited: 183
Loss of function mutations of BCOR in classical Hodgkin lymphoma. Leukemia & lymphoma. 2021 Academic Article GET IT
Times cited: 1
Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformation. Nature immunology. 2021 Academic Article GET IT
Times cited: 17
An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities. Blood cancer discovery. 2021 Academic Article GET IT
Times cited: 14
Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture. Nature. 2020 Academic Article GET IT
Times cited: 95
Epigenetic Mechanisms in Leukemias and Lymphomas. Cold Spring Harbor perspectives in medicine. 2020 Review GET IT
Times cited: 10
TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate. Cell. 2020 Academic Article GET IT
Times cited: 40
Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response. Cancer cell. 2020 Academic Article GET IT
Times cited: 70
Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL. Nature communications. 2019 Academic Article GET IT
Times cited: 46
Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition. Cancer discovery. 2019 Academic Article GET IT
Times cited: 161
TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis. Cancer discovery. 2018 Academic Article GET IT
Times cited: 101
Ex vivo synthetic immune tissues with T cell signals for differentiating antigen-specific, high affinity germinal center B cells. Biomaterials. 2018 Academic Article GET IT
Times cited: 23
Enhancer of zeste homolog 2 (EZH2) inhibitors. Leukemia & lymphoma. 2018 Review GET IT
Times cited: 114
EZH2 enables germinal centre formation through epigenetic silencing of CDKN1A and an Rb-E2F1 feedback loop. Nature communications. 2017 Academic Article GET IT
Times cited: 109
Genetic and epigenetic inactivation of SESTRIN1 controls mTORC1 and response to EZH2 inhibition in follicular lymphoma. Science translational medicine. 2017 Academic Article GET IT
Times cited: 39
Modular Immune Organoids with Integrin Ligand Specificity Differentially Regulate Ex Vivo B Cell Activation. ACS biomaterials science & engineering. 2017 Academic Article GET IT
Times cited: 26
Multi-tiered Reorganization of the Genome during B Cell Affinity Maturation Anchored by a Germinal Center-Specific Locus Control Region. Immunity. 2016 Academic Article GET IT
Times cited: 89
EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis. Cancer cell. 2016 Academic Article GET IT
Times cited: 166
Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. The Journal of clinical investigation. 2016 Academic Article GET IT
Times cited: 110
Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status". Nature medicine. 2016 Letter GET IT
Times cited: 7
Loss of BAP1 function leads to EZH2-dependent transformation. Nature medicine. 2015 Academic Article GET IT
Times cited: 253
IL10 receptor is a novel therapeutic target in DLBCLs. Leukemia. 2015 Academic Article GET IT
Times cited: 53
Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance. Oncogene. 2014 Academic Article GET IT
Times cited: 42
Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia. Science translational medicine. 2014 Academic Article GET IT
Times cited: 98
Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy. Breast cancer research : BCR. 2013 Academic Article GET IT
Times cited: 28
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer cell. 2013 Academic Article GET IT
Times cited: 608
p42/p44 MAPK-mediated Stat3Ser727 phosphorylation is required for progestin-induced full activation of Stat3 and breast cancer growth. Endocrine-related cancer. 2013 Academic Article GET IT
Times cited: 63
Targeting Stat3 induces senescence in tumor cells and elicits prophylactic and therapeutic immune responses against breast cancer growth mediated by NK cells and CD4+ T cells. Journal of immunology (Baltimore, Md. : 1950). 2012 Academic Article GET IT
Times cited: 36
Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer. BMC cancer. 2012 Academic Article GET IT
Times cited: 34
Novel role of signal transducer and activator of transcription 3 as a progesterone receptor coactivator in breast cancer. Steroids. 2010 Academic Article GET IT
Times cited: 23
Progesterone receptor induces ErbB-2 nuclear translocation to promote breast cancer growth via a novel transcriptional effect: ErbB-2 function as a coactivator of Stat3. Molecular and cellular biology. 2010 Academic Article GET IT
Times cited: 85
Transactivation of ErbB-2 induced by tumor necrosis factor alpha promotes NF-kappaB activation and breast cancer cell proliferation. Breast cancer research and treatment. 2009 Academic Article GET IT
Times cited: 30
Activation of Stat3 by heregulin/ErbB-2 through the co-option of progesterone receptor signaling drives breast cancer growth. Molecular and cellular biology. 2008 Academic Article GET IT
Times cited: 51
TNF alpha acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-kappa B-dependent pathways. Experimental cell research. 2007 Academic Article GET IT
Times cited: 120
Progestin-induced caveolin-1 expression mediates breast cancer cell proliferation. Oncogene. 2006 Academic Article GET IT
Times cited: 43

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Preventing follicular lymphoma progression and transformation through precision therapy awarded by National Cancer Institute Principal Investigator 2022 - 2027
Epigenetic basis and therapeutic interdiction of FL progression awarded by Lymphoma Research Foundation Principal Investigator 2023 - 2026
Utilizing EZH2 Inhibition to Improve Immune Therapies in Follicular Lymphoma awarded by Follicular Lymphoma Foundation Principal Investigator 2022 - 2024
Preventing follicular lymphoma progression and transformation through precision therapy awarded by Leukemia & Lymphoma Society, Inc. Principal Investigator 2021 - 2024

Restoring lymphoma immunosurveillance by combined EZH2 inhibition and immunotherapy. awarded by Leukemia & Lymphoma Society, Inc. Key Personnel 2021 - 2024

Lymph node-targeted multistage chemoimmunotherapy for lymphoma awarded by National Cancer Institute Principal Investigator Subaward 2020 - 2025

more ...

less ...

Background

education and training

Ph.D., University of Buenos Aires (Argentina) 2010

Contact

full name

Wendy Beguelin

primary email

web2002@med.cornell.edu

VIVO Weill Cornell Medical College

Wendy Beguelin Assistant Professor of Pharmacology in Medicine

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

Phone

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email